Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
-0.84% $3.55
America/New_York / 17 apr 2024 @ 15:40
FUNDAMENTALS | |
---|---|
MarketCap: | 185.86 mill |
EPS: | -0.840 |
P/E: | -4.23 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 52.35 mill |
Avg Daily Volume: | 0.0796 mill |
RATING 2024-04-17 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.23 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.09x |
Company: PE -4.23 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 3.35 - 3.83 ( +/- 6.74%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Ashman Philip | Sell | 12 103 | Common Stock |
2024-03-11 | Werner Jason M. | Buy | 1 800 | Restricted Stock Units |
2024-03-11 | Wood Todd Michael | Buy | 125 000 | Performance-Based Restricted Stock Units |
2024-03-11 | Wood Todd Michael | Buy | 125 000 | Restricted Stock Units |
2024-03-11 | Eiswirth Richard S Jr | Buy | 14 700 | Restricted Stock Units |
INSIDER POWER |
---|
26.98 |
Last 77 transactions |
Buy: 33 555 909 | Sell: 20 075 544 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.55 (-0.84% ) |
Volume | 0.0014 mill |
Avg. Vol. | 0.0796 mill |
% of Avg. Vol | 1.816 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.